Abstracts tagged "sleep"

Abstract Number: 0969 • ACR Convergence 2023
Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study
Pin-Chia Huang¹, Katharine Ching Chung², Zachary S Peacock³ and Kevin Sheng-Kai Ma⁴, ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²University of Pittsburgh Medical Center, Mckeesport, PA, ³Oral and Maxillofacial Surgery, Massachusetts General Hospital, Harvard School of Dental Medicine, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-α (TNF-α) plays a role in the pathogenesis of and serves as a biomarker for obstructive sleep apnea (OSA). Moreover, patients with…
Abstract Number: 1191 • ACR Convergence 2023
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee
Guang-Liang Jiang¹ and Feng Xu², ¹Xgene Pharmaceutical Inc., Lexington, MA, ²Xgene Pharmaceutical Inc., Altos Hills, CA
Background/Purpose: Globally osteoarthritis affects about 302 million patients, knee osteoarthritis accounts for 263 million and ranks the highest in disability and pain compared to OA…
Abstract Number: 0204 • ACR Convergence 2022
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
Jessica Leung¹, Claire Owen², David Liew³ and Russell Buchanan³, ¹Austin Health, Preston, Victoria, Australia, ²Austin Health, Malvern East, Australia, ³Austin Health, Heidelberg, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients…
Abstract Number: 0387 • ACR Convergence 2022
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Marta Ibañez Martinez¹, Sonia Pastor Navarro², Olga Compán Fernández², Belén Miguel Ibáñez², Ana Isabel Turrión Nieves², Susana Gómez Castro¹, Olga Martínez González², Cristina Hidalgo Calleja², Esther Toledano Martinez³ and Carlos Montilla Morales², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
Abstract Number: 1451 • ACR Convergence 2022
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Christina Stankey¹, Philip Chu², Alicia Hinze³, Lily McMorrow¹, Alia El-Qunni¹, Deepali Sen¹, Seth Eisen¹, Yo-El Ju¹ and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Duke University Hospital, Raleigh, NC, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Poor sleep quality is a common complaint of patients with SLE. Although chronic sleep disruption is known to drive circadian rhythm disorders, the effects…
Abstract Number: 1714 • ACR Convergence 2022
The Circadian Clock Gene Bmal1 Negatively Regulates Autoantibody Production in SLE
Shuichiro Nakabo¹, Donavon Sandoval-Heglund¹, Victoria Hoffmann², Mingzeng Zhang¹, Norio Hanata¹, Zerai Manna¹, Elaine Poncio¹, Sarfaraz Hasni³ and Mariana Kaplan⁴, ¹NIAMS/NIH, Bethesda, MD, ²ORS/ORF/NIH, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs including kidney and skin. While its etiology and pathogenesis are still…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
Abstract Number: 0656 • ACR Convergence 2021
A Survey Based Descriptive Study to Assess the Quality of Sleep in Rheumatic Patients
Kezia Sam¹, David Lans² and Fulvia Milite¹, ¹White Plains Hospital, White Plains, NY, ²New York Medical College, Valhalla, NY, New Rochelle, NY
Background/Purpose: Sleeping difficulties although common in rheumatic patients, have often been overlooked presuming it to be part of a chronic illness. We conducted a survey-based…
Abstract Number: 0894 • ACR Convergence 2021
Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Deborah Da Costa¹, Josée Savard², Elham Rahme¹ and Paul R Fortin³, ¹McGill University, Montréal, QC, Canada, ²Université Laval, Québec City, QC, Canada, ³CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morning awakenings are prevalent among persons with lupus and have been shown to contribute…
Abstract Number: 1059 • ACR Convergence 2021
The Association of Pain and Sleep in Relation to Depressive Symptoms Among Older Adults with Arthritis
Uyen-Sa Nguyen¹, Cameron Zielke² and Noah Peeri³, ¹University of North Texas Health Science Center, School of Public Health, Arlington, TX, ²University of Illinois-Chicago, Fort Worth, TX, ³University of North Texas Health Science Center, Fort Worth
Background/Purpose: The primary symptom of arthritis is chronic pain which has widespread consequences on an individual’s sleep and mental health. Research suggests that sleep and…
Abstract Number: 1590 • ACR Convergence 2021
Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases
Niti Pawar¹, Kimberly E. Taylor¹, Monica Yang¹, Parakkal Deepak², Wooseob Kim², Michael Paley³, Mehrdad Matloubian¹, Alex Carividi¹, Matthew Ciorba², Emanuel Demissie¹, Alia A. El-Qunni,², Katherine Huang², Baylee Kinnett², Lily E. McMorrow², Diana Paez¹, Abbey Rose², Rebecca E. Schriefer², Ali H Ellebedy², Alfred Kim², Mary Nakamura⁴, Patricia Katz¹ and Lianne Gensler⁵, ¹University of California San Francisco, San Francisco, CA, ²Washington University School of Medicine, St. Louis, MO, ³Washington University in St. Louis, Olivette, MO, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: As the COVID-19 pandemic unfolded, people across the world experienced a psychological burden with social confinement, concerns about health, potential infection, jobs, financial difficulty,…
Abstract Number: 1666 • ACR Convergence 2021
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Patricia Katz¹, Sarah Patterson², Mary Nakamura³, Aric Prather¹, Laura Trupin⁴, Stephanie Rush¹ and Katie Stone¹, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UCSF/SFVAHCS, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA
Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…
Abstract Number: 0118 • ACR Convergence 2021
Multidimensional Phenotypes of Sleep Quality Using the Pittsburg Quality Sleep Index and Associations Among Sleep Dimensions and Symptoms in Women Diagnosed with Fibromyalgia
Victoria Menzies, Debra Lynch Kelly and Miichael Weaver, University of Florida, Gainesville, FL
Background/Purpose: There are over 10 million people in the United States suffering with fibromyalgia syndrome (FMS). Individuals with FMS typically report multiple concurrent symptoms including…
Abstract Number: 0476 • ACR Convergence 2021
Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
Marc Martel¹, Lilach Eyal Waldman¹, Romina Sotoodeh¹, Antonio Vigano¹, Yola Moride², Michelle Canac-Marquis³, Rihab Gamaoun³, Maja Kalaba⁴, Pierre Beaulieu², Julie Desroches², Mark A. Ware⁴, Jordi Perez³, Yoram Shir³ and Mary-Ann Fitzcharles¹, ¹McGill University, Montréal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴Canopy Growth Corporation, Montréal, QC, Canada
Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical…
Abstract Number: 0477 • ACR Convergence 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
Gregory Sullivan¹, Mary Kelley², Annabelle Iserson¹, Perry Peters², Ashild Peters², Candace Flint¹, Judy Gendreau³, Herb Harris¹, Ben Vaughn⁴ and Seth Lederman⁵, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceuticals, Inc., San Diego, CA, ³Gendreau Consulting, LLC, Poway, CA, ⁴Rho, Inc., Cary, NC, ⁵Tonix Pharmaceuticals, Inc., South Dartmouth, MA
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, fatigue, and nonrestorative sleep, a symptom constellation suggestive of a pathological disturbance in central pain processing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].